- Home
- MPLX vs BDX Comparison
MPLX vs BDX Comparison
Compare MPLX & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPLX | BDX |
|---|---|---|
| Founded | 2012 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0B | 55.5B |
| IPO Year | 2012 | 1962 |
Fundamental Metrics
Financial Performance| Metric | MPLX | BDX |
|---|---|---|
| Price | $56.21 | $201.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $58.83 | ★ $207.13 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 02-03-2026 | 02-09-2026 |
| Dividend Yield | ★ 7.72% | 2.08% |
| EPS Growth | ★ 11.31 | N/A |
| EPS | 4.72 | ★ 5.82 |
| Revenue | $11,632,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $18.07 | $4.01 |
| Revenue Next Year | $4.09 | $3.38 |
| P/E Ratio | ★ $11.82 | $34.69 |
| Revenue Growth | 5.53 | ★ 8.24 |
| 52 Week Low | $44.60 | $162.29 |
| 52 Week High | $57.16 | $251.99 |
Technical Indicators
Market Signals| Indicator | MPLX | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 61.99 | 49.86 |
| Support Level | $54.36 | $195.63 |
| Resistance Level | $56.10 | $208.00 |
| Average True Range (ATR) | 1.01 | 4.47 |
| MACD | 0.11 | -0.73 |
| Stochastic Oscillator | 79.48 | 40.95 |
Price Performance
Historical ComparisonAbout MPLX MPLX LP
MPLX is a partnership that owns pipelines and gathering and processing assets with extensive holdings in the Appalachian and Permian regions. The asset base is made up of crude oil and refined products assets dropped down from Marathon Petroleum, its sponsor, and natural gas and natural gas liquids gathering and processing assets that were purchased or built.
About BDX Becton Dickinson and Company
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.